FR13C0057I1 - - Google Patents

Info

Publication number
FR13C0057I1
FR13C0057I1 FR13C0057C FR13C0057I1 FR 13C0057 I1 FR13C0057 I1 FR 13C0057I1 FR 13C0057 C FR13C0057 C FR 13C0057C FR 13C0057 I1 FR13C0057 I1 FR 13C0057I1
Authority
FR
France
Prior art keywords
active compounds
inefficacious
nedocromil
abandonment
prophylactically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0057I1 publication Critical patent/FR13C0057I1/fr
Application granted granted Critical
Publication of FR13C0057I2 publication Critical patent/FR13C0057I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

The use of solid, pharmaceutically acceptable salts of cromoglycic acid and/or nedocromil as carriers in a therapeutically and prophylactically inefficacious amount in suspension aerosol formulations of pharmaceutical active compounds improves the dispersion properties, increases the chemical and physical stability of moisture-sensitive active compounds, makes possible a more accurate dosage, in particular even of low-dose active compounds, and as a rule permits the abandonment of surface-active agents.
FR13C0057C 1998-08-04 2013-10-15 AEROSOL FORMULATIONS FOR MEDICAL USE Active FR13C0057I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH163398 1998-08-04
PCT/CH1999/000360 WO2000007567A1 (en) 1998-08-04 1999-08-02 Medicinal aerosol formulations

Publications (2)

Publication Number Publication Date
FR13C0057I1 true FR13C0057I1 (en) 2013-11-15
FR13C0057I2 FR13C0057I2 (en) 2020-04-03

Family

ID=4215022

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0057C Active FR13C0057I2 (en) 1998-08-04 2013-10-15 AEROSOL FORMULATIONS FOR MEDICAL USE

Country Status (19)

Country Link
US (1) US6475467B1 (en)
EP (1) EP1102579B1 (en)
JP (1) JP4672143B2 (en)
CN (1) CN1150890C (en)
AT (1) ATE234604T1 (en)
AU (1) AU749697B2 (en)
BE (1) BE2013C027I2 (en)
CA (1) CA2338680C (en)
CY (1) CY2012033I1 (en)
DE (1) DE59904648D1 (en)
DK (1) DK1102579T3 (en)
ES (1) ES2193726T3 (en)
FR (1) FR13C0057I2 (en)
LU (1) LU92254I2 (en)
NO (2) NO328096B1 (en)
NZ (1) NZ509489A (en)
PT (1) PT1102579E (en)
WO (1) WO2000007567A1 (en)
ZA (1) ZA200100569B (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
PE20010720A1 (en) * 1999-12-11 2001-07-26 Glaxo Group Ltd MEDICATION DISTRIBUTOR
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2001089480A1 (en) 2000-05-22 2001-11-29 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FR2812545B1 (en) * 2000-08-03 2003-03-28 Air Liquide Sante Int INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
PL207870B1 (en) * 2000-10-12 2011-02-28 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
HUP0301377A3 (en) * 2000-10-31 2005-12-28 Boehringer Ingelheim Pharma Combination pharmaceutical composition in form of inhalative solution containing a tiotropium salt
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
CN100496608C (en) * 2001-03-30 2009-06-10 洁垢技术有限公司 Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
HUE044926T2 (en) * 2002-03-01 2019-11-28 Chiesi Farm Spa Formoterol superfine formulation
DE10212264A1 (en) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (en) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations containing an anticholinergic
DE10214264A1 (en) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations of an anhydrate
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
JP5160018B2 (en) 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
ATE498604T1 (en) * 2002-12-10 2011-03-15 Sunovion Pharmaceuticals Inc AEROSOL FORMULATION COMPRISING LEVALBUTEROL L-TARTRATE SALT
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
CN1292748C (en) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 Timepidium bromide inhalant powders and their preparing process
JP4708332B2 (en) * 2003-03-20 2011-06-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Formulation for metered dose inhalers using hydrofluoroalkane as propellant
US20060293293A1 (en) * 2003-05-22 2006-12-28 Altana Pharma Ag Salmeterol and ciclesonide combination
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US8435497B2 (en) 2003-06-13 2013-05-07 Takeda Gmbh Formoterol of and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
AU2003254429A1 (en) * 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
AU2004271744B2 (en) * 2003-09-16 2010-07-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
US20070189979A1 (en) * 2003-09-18 2007-08-16 Norton Healthcare Limited T/A Ivax Pharmaceuticals Particles
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
RU2440813C2 (en) * 2004-02-06 2012-01-27 Меда Фарма Гмбх Унд Ко.Кг Combination (versions) and pharmaceutical preparation for treating upper respiratory tract diseases
DE602005007708D1 (en) * 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg NEW COMBINATION OF ANTICHOLINERGEN AND BETA MIMETIKA FOR THE CONTROL OF RESPIRATORY DISEASES
JP4700014B2 (en) * 2004-02-06 2011-06-15 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Combination of anticholinergic agent and type 4 phosphodiesterase for the treatment of respiratory diseases
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
JP2007524698A (en) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト Combination of ciclesonide and glycopyrronium
EP1740188A1 (en) * 2004-04-20 2007-01-10 Altana Pharma AG Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
HUE042304T2 (en) * 2004-04-23 2019-06-28 Cydex Pharmaceuticals Inc DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
ITRM20040268A1 (en) * 2004-05-31 2004-08-31 Italchimici S P A PHARMACEUTICAL FORMULATION OF A STABLE FORMOTEROL SOLUTION BY INHALATION AND ON ITS PREPARATION.
EA013428B1 (en) * 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
JP3955868B2 (en) * 2004-12-27 2007-08-08 株式会社キングジム Binding tools such as documents
DE102005029390A1 (en) * 2005-06-23 2007-01-04 Beiersdorf Ag Combination, useful as cosmetic deodorant and antitranspirants, comprises glycopyrronium bromide and active materials e.g. boundary surface-active substances, polyols and hydrocolloids
EP1835812B1 (en) 2004-12-27 2011-08-17 Beiersdorf AG Glycopyrrolate in cosmetic preparations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
EP1863476B1 (en) * 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP1879571A1 (en) * 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
DK1881980T3 (en) 2005-05-02 2012-10-01 Boehringer Ingelheim Int New crystalline forms of tiotropium bromide
ZA200711040B (en) * 2005-06-03 2009-04-29 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
DE102006017320A1 (en) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
ES2298049B1 (en) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO.
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
DE102007002121B4 (en) * 2007-01-10 2008-12-11 Dräger, Karl-Heinz Use of a liquefied gas mixture as non-combustible propellant gas for ultrafine distribution of a stimulant or warfare agent
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111926T3 (en) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
TR200907237A2 (en) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropium dry powder combination
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TR200907914A2 (en) 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut Pharmaceutical composition in the form of a dry powder containing corticosteroid.
AR079451A1 (en) 2009-12-18 2012-01-25 Nycomed Gmbh COMPOUNDS 3,4,4A, 10B-TETRAHIDRO-1H-TIOPIRANO [4,3-C] ISOQUINOLINA
EP2515853B1 (en) * 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
ES2468840T7 (en) * 2009-12-23 2023-11-29 Chiesi Farm Spa Combination therapy for COPD
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
TR200909791A2 (en) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Pharmaceutical composition containing salmeterol and fluticasone
TR200909789A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Dry powder combination containing tiotropium, budesonide and a chromoglycic acid derivative combination
TR200909792A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Dry powder combination containing tiotropium, corticosteroid and a combination of chromoglycic acid derivative
TR200909793A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Combination of dry powder containing a combination of tiotropium, mometasone and a chromoglycic acid derivative.
TR200909790A2 (en) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Combination of dry powder containing a combination of tiotropium, formoterol and a chromoglycic acid derivative.
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
JP2014519519A (en) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel 3,4,4a, 10b-tetrahydro-1H-thiopyrano [4,3-c] isoquinoline compounds
AR086915A1 (en) 2011-06-17 2014-01-29 Nycomed Gmbh DERIVATIVES OF FTALAZINONA-PIRROLOPIRIMIDINACARBOXAMIDA AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR086745A1 (en) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
US9029382B2 (en) 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
HUE039513T2 (en) 2013-12-30 2019-01-28 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
DK3104853T3 (en) 2014-02-10 2019-12-09 Respivant Sciences Gmbh TREATMENT WITH MAST CELL STABILIZERS FOR SYSTEMIC DISORDERS
SI3104854T1 (en) * 2014-02-10 2020-09-30 Respivant Sciences Gmbh Mast cell stabilizers for lung disease treatment
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN110139646A (en) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 For treating the Cromoglycic acid composition of the chronic cough as caused by idiopathic pulmonary fibrosis
EP3909582B1 (en) 2016-09-19 2023-05-24 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising indacaterol
BR112019005168A2 (en) 2016-09-19 2019-06-11 Mexichem Fluor Sa De Cv pharmaceutical composition, sealed container, metered dose inhaler, and methods for treating a patient suffering or likely to suffer from a respiratory disorder, for improving the stability of a pharmaceutical composition and the aerosolization performance of a pharmaceutical composition global warming potential of a pharmaceutical composition
US10888546B2 (en) * 2016-09-19 2021-01-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolyn compositions for treatment of pulmonary fibrosis
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
WO2018069887A1 (en) * 2016-10-14 2018-04-19 Glenmark Specialty S.A. Nebulizable compositions of tiotropium and formoterol
UA122811C2 (en) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська PHARMACEUTICAL COMPOSITION
CN112972384B (en) * 2019-12-02 2022-03-18 长风药业股份有限公司 Preparation method of glycopyrronium bromide and indacaterol bulk drug micro-powder mixture
EP4069189A1 (en) 2019-12-02 2022-10-12 Chiesi Farmaceutici S.p.A. Stainles steel can for pressurised metered dose inhalers
WO2023227782A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) 1956-03-21 1900-01-01
BE556587A (en) 1957-01-31 1957-04-11
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IL51314A (en) 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
NL7708731A (en) 1976-08-13 1978-02-15 Montedison Spa PROCESS FOR THE PREPARATION OF NEW DRIVER COMPOSITIONS FOR AEROSOLS.
CA1075854A (en) 1976-08-16 1980-04-22 Charles W. Simons Aerosol propellants for personal products
FR2390951A1 (en) 1977-05-17 1978-12-15 Oreal NEW COSMETIC COMPOSITIONS IN THE FORM OF AEROSOL LACQUERS TO FIX THE HAIR
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS61158919A (en) 1984-12-28 1986-07-18 Taisho Pharmaceut Co Ltd Remedy for athlete's foot
GB8820398D0 (en) * 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
IE62780B1 (en) * 1988-09-10 1995-02-22 Fisons Plc Inhalation devices with a reduced risk of blockage
DE3839258A1 (en) * 1988-11-21 1990-05-23 Norbert Sass Process for the production of a suspension aerosol
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
DE4003272A1 (en) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS
ES2096653T3 (en) * 1990-06-29 1997-03-16 Fisons Plc COMPOSITIONS OF PRESSURIZED AEROSOL.
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
US5753208A (en) * 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE69218455T2 (en) * 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. AEROSOL COMPOSITIONS FOR MEDICAL SUSPENSIONS
DE59206234D1 (en) 1991-12-31 1996-06-13 Hoechst Ag Medical aerosol formulation
SE523661C2 (en) 1992-02-05 2004-05-04 American Pacific Corp Gas-liquid mixture intended for use as a fire extinguishing agent
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9214765D0 (en) 1992-07-11 1992-08-26 Smithkline Beecham Plc Pressurised aerosol formulation
WO1994003056A1 (en) 1992-07-31 1994-02-17 Ian Alexander Edwin Maccormick Aerosol insecticide composition
KR100428914B1 (en) 1994-12-22 2004-06-16 아스트라제네카 악티에볼라그 Aerosol Drug Formulations
WO1996032099A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
DE19616573C2 (en) * 1996-04-25 1999-03-04 Pari Gmbh Use of subcritical blowing agent mixtures and aerosols for the micronization of drugs with the help of dense gases
FR2764899B1 (en) 1997-06-19 2001-04-06 Boehringer Ingelheim Alimentai NEW PROPELLER MIXTURE AND AEROSOL FOOD PREPARATIONS CONTAINING IT

Also Published As

Publication number Publication date
CY2012033I2 (en) 2015-08-05
PT1102579E (en) 2003-07-31
NO2012019I2 (en) 2014-06-02
JP2002522374A (en) 2002-07-23
FR13C0057I2 (en) 2020-04-03
WO2000007567A1 (en) 2000-02-17
DK1102579T3 (en) 2003-07-14
ES2193726T3 (en) 2003-11-01
BE2013C027I2 (en) 2018-12-04
CA2338680A1 (en) 2000-02-17
NO2012019I1 (en) 2012-12-27
AU4893999A (en) 2000-02-28
NO20010531D0 (en) 2001-01-31
AU749697B2 (en) 2002-07-04
LU92254I2 (en) 2013-09-17
JP4672143B2 (en) 2011-04-20
CY2012033I1 (en) 2015-08-05
ATE234604T1 (en) 2003-04-15
ZA200100569B (en) 2001-09-26
EP1102579A1 (en) 2001-05-30
DE59904648D1 (en) 2003-04-24
CA2338680C (en) 2008-10-14
NO20010531L (en) 2001-01-31
CN1150890C (en) 2004-05-26
CN1315852A (en) 2001-10-03
EP1102579B1 (en) 2003-03-19
US6475467B1 (en) 2002-11-05
NZ509489A (en) 2002-10-25
NO328096B1 (en) 2009-12-07

Similar Documents

Publication Publication Date Title
FR13C0057I1 (en)
BR0014320A (en) Compositions of therapeutic substances soluble in tocol
NZ509328A (en) Medicinal aerosol formulations
PT1087750E (en) Pharmaceutical formulations for aerosols with two or more active substances
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
ATE334663T1 (en) MEDICINAL COMPOSITION WITH DELAYED RELEASE
DZ2744A1 (en) Distribution of an aerosolized active agent.
CY1107350T1 (en) MULTIPLE DOSAGE INHIBITOR DRY POWDER
BRPI0113331B8 (en) phenylalanine derivatives or their pharmaceutically acceptable salts, alpha 4 integrin antagonist, therapeutic agent or preventive agent for inflammatory diseases, and pharmaceutical composition
TR200001942T2 (en) Opioid agonist / antagonist combinations
ZA200307161B (en) Medical aerosol formulations
WO2001041737A3 (en) Solid oral dosage form
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
GB0016876D0 (en) Novel formulation
WO2000010526A3 (en) New oral formulation for 5-ht4 agonists or antagonists
PT1077703E (en) FORMS OF ORAL MEDICINES WITH REPRODUCTIVE RELEASE OF THE ACTIVE SUBSTANCE GATIFLOXACIN OR ITS PHARMACEUTICALLY ACCEPTANT SALTS OR HYDRATES
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
ATE353224T1 (en) DISPENSING DEVICE FOR A COMPOSITION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE
EP1325903A4 (en) 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
BE2016C017I2 (en)
ATE342734T1 (en) ADENOSINE A1 ANTAGONISTS AGAINST MALE STERILITY
WO2002038133A3 (en) Compositions containing hydrolytically unstable compounds
TR200102279T2 (en) Pharmaceutical effervescent (foaming) formulation containing metamizole.
AR033862A1 (en) MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT
ATE286716T1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING SALMETEROL